NewAmsterdam Pharma Company N.V. (NAMS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Is NewAmsterdam Pharma Company N.V. stock overvalued or undervalued in 2026?
As of November 3, 2026, NewAmsterdam Pharma Company N.V. (NAMS) trades at $19.90 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: NewAmsterdam Pharma Company N.V.
Market cap $2B · 52 weeks $20 – $41 (53 % below the high) · P/E no earnings · Dividend none · Next earnings November 4, 2026 · expected EPS -$0.49 · Closing price, Nov 3 · accounts published Aug 5.
- Valuation: P/Sales 115× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 6.2 %, fails.
- Market cap / Cash 3.6×, fails.
- Cash Runway 52 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $1.29, info.
Against its peers (reference peers) — NewAmsterdam Pharma Company N.V.: P/E —; EV/EBITDA —; ROIC -38.7 %; $2.3B. Aurinia Pharmaceuticals Inc. (P/E 7.2×; EV/EBITDA 11.4×; ROIC 20.9 %; $2.2B), ADMA Biologics, Inc. (P/E 15.9×; EV/EBITDA 10.9×; ROIC 27.6 %; $2.5B), Harmony Biosciences Holdings, Inc. (P/E 12.0×; EV/EBITDA 6.7×; ROIC 15.0 %; $2.2B).
Profitability
| Return on Equity | -38.33% |
| Return on Invested Capital | -38.70% |
| Return on Assets | -36.84% |
| Gross Margin | 92.15% |
| Operating Margin | -3,432.20% |
| Net Margin | -3,644.21% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 9.03 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 26.64 |
Price Performance
| 1 month | -14.21% |
| 3 months | -29.31% |
| Year-to-date | -44.24% |
| 1 year | -46.45% |
| 3 years | +89.53% |
| 5 years | +98.98% |
Related companies: MDGL · VKTX · DNLI · AMLX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of NAMS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks